Camila888
Posted - 3 days ago
😏🚀 MYNZ We know the date of the reverse split (RS) if there will be one, but possibly a Nasdaq extension will be granted. Last time it traded, 50 million and 19 million heavy shorts attacked. Now, it has huge credibility after the TMO partnership and the meeting. The company will decide by November 25th whether or not to do an RS based on Nasdaq's response. Anyway, after the RS, I'm not worried about what happens next. A $210 billion partner TMO signing a deal with a penny stock has never happened before. I will be loading heavy on Monday. This will go to the moon like the DRUG stock recently did. The price target (PT) is $50. The squeeze will be parabolic. $AYTU $IMRN
KoleSalinas
Posted - 1 week ago
💥 Huge news expected for MYNZ soon 💥 Nov 12: 51M volume, +28%, with 19M short volume. With everyone awaiting the meeting results, I have a strong feeling the r/s extension will be pushed out another 180 days. Mainz Biomed (MYNZ) has partnered with Thermo Fisher (TMO, $209.2B market cap, trading at ~$546.92) to develop a next-gen colorectal cancer screening tool for global markets. Thermo Fisher’s $42.4B revenue and advanced tech will boost MYNZ’s mRNA-based assays, achieving 85% detection for advanced adenomas, compared to competitors' 43% and 20%. With CRC cases up 500% in young people, MYNZ is leading early detection. Sentiment: Positive 1. Strategic partnership with industry giant Thermo Fisher 2. Access to Thermo Fisher's advanced tech 3. Potential for global commercialization 4. Development of home collection screening capability Win-win as TMO steps into the CRC market, too. Calling all apes, let’s crush the short sellers—this bull run is ours. $AYTU $IMRN
topstockalerts
Posted - 10/29/24
Pre Market Top Gainers PT2 $AREB $IMRN $NBY $VFC $DJT
PharmaExpert
Posted - 10/22/24
$AKBA, $PHUN, $IMRN, $INDP, $CYCC 🔥🔥🔥🔥🔥
PenkeTrading
Posted - 1 month ago
I found you an Oversold RSI (Relative Strength Index) on the daily chart of Immuron Ltd ADR. Is that bullish or bearish? $IMRN #Immuron #RsiOversold #NASDAQ
LewisDaKat
Posted - 1 month ago
$IMRN News Article Immuron CEO, Steven Lydeamore participation in Maxim Virtual Healthcare Conference https://marketwirenews.com/news-releases/immuron-ceo-steven-lydeamore-participation-in-maxim--8681244350341717.html $IMRN
themacromindset
Posted - 1 month ago
Immuron CEO, Steven Lydeamore participation in Maxim Virtual Healthcare Conference $IMRN
briefingcom
Posted - 1 month ago
Gapping up: $WOLF +29.3% $ERIC +10.2% $IMRN +6.2% $WBA +5.2%
DonCorleone77
Posted - 1 month ago
$IMRN Immuron reports Q3 sales of Travelan up 13% vs. Q2 Immuron Limited announced continued strong sales growth of Travelan, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal tract. Flavio Palumbo, Chief Commercial Officer, said, "As anticipated, we are achieving strong growth in North America with continued growth in Australia. We have secured core ranging in another nine pharmacy banner groups in Australia. We had our strongest monthly sales on Amazon in the US. We now have distribution in ten pharmacy/grocery retailers in Canada." Global sales of Travelan for the September 2024 quarter were AUD$1.5M, up 13% on prior quarter; for Australia, Travelan sales increased 3% to AUD$1.007M during the September 2024 quarter vs. AUD$0.983M for the June 2024 quarter. In North America, Travelan sales increased 48% to AUD$0.456M in the September 2024 quarter vs. AUD$0.309M in the June 2024 quarter.
G101SPM
Posted - 1 month ago
$IMRN $2.21 last. DAC (dollar average cost) (2) $2.32 (5.30.23). EXIT $6.50 (long term). UPDATE: Immuron announces Travelan has continued strong sales growth. ^^ Global September 2024 Quarter AUD$1.5 million up 13% on prior quarter Australia. ^^ September 2024 Quarter AUD$1.0 million up 3% on prior quarter North America. ^^ September 2024 Quarter AUD$0.5 million up 48% on prior quarter.
themacromindset
Posted - 1 month ago
$IMRN Immuron Travelan® continued strong sales growth
topstockalerts
Posted - 1 month ago
Pre Market Top Gainers PT2 $INAB $JSPR $IMRN $WHLR $GMM
topstockalerts
Posted - 1 month ago
Pre Market Top Gainers PT2 $PW $AMLI $BLMZ $AKAN $IMRN
Red2Profit
Posted - 1 month ago
$IMRN News! Halt up
sevendrax77
Posted - 1 month ago
$IMRN what happened? News?
risingstarsbynature
Posted - 09/26/24
$IMRN buy Rating
https://fox40.com/business/press-releases/ein-presswire/745762816/mecca-capital-fund-mecca-capital-partners-initiates-a-buy-rating-on-immuron-limited-nasdaq-imrn/
ButterCapital
Posted - 09/23/24
$IMRN buy order hit
Doozio
Posted - 2 months ago
$IMRN FRYdays during 🧠⏰♾️
G101SPM
Posted - 2 months ago
$IMRN $2.74 bid. DAC (2) $2.32 (5.30.23). EXIT $6.50 long term. UPDATE: Announced it has received favorable feedback from FDA on the pre-IND (investigational new drug) information package to support the clinical development of IMM-529.
Stock_Titan
Posted - 2 months ago
$IMRN Immuron Plans Phase 2 Trial for IMM-529 following FDA review
https://www.stocktitan.net/news/IMRN/immuron-plans-phase-2-trial-for-imm-529-following-fda-ztuuapvn4j0c.html
Doozio
Posted - 08/30/24
$IMRN chop chop huckleberries thiiiiiin to win in 🧠⏰
PharmaExpert
Posted - 3 months ago
$AKBA, $STXS, $BMRA, $IMRN, $AGRX 🔥🔥🔥🔥🔥
Stock_Titan
Posted - 3 months ago
$IMRN Immuron Announces New U.S. Department of Defense Research Award for Naval Medical Research Command and Walter Reed Army Institute of Research to advance Travelan®
https://www.stocktitan.net/news/IMRN/immuron-announces-new-u-s-department-of-defense-research-award-for-uhvmurmhlhik.html
G101SPM
Posted - 3 months ago
$IMRN $2.27 last. DAC (2) $2.32. EXIT $6.50 (long term) UPDATE: Hosting webinar on Thursday 8th August 2024, 11:00am Australian Eastern Standard Time (9:00am AWST). note: Chief Executive Officer, Steven Lydeamore will provide an update on additional data analysis of IMM-124E (Travelan®) Phase 2 trial and next steps.
G101SPM
Posted - 4 months ago
#SPMNOTES Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now * $IMRN $ 2.68 * $CVKD $0.450499 * Hold long positions The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.
Kevin_Gough
Posted - 4 months ago
$IMRN Great news!!!
Kevin_Gough
Posted - 4 months ago
$IMRN Great news!!!
DonCorleone77
Posted - 4 months ago
$IMRN Immuron announces record Travelen sales globally Immuron announced record sales of Travelan, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal tract. Australia: Sales of Travelan increased 236% to AUD $3.7 million for the full financial year to June 2024 compared to AUD $1.1 million for FY23. Sales of Travelan increased 209% to AUD $1.0 million for the June 2024 Quarter compared to AUD $0.3 million for the June 2023 Quarter. Consistent with the increase in June 2024 quarter sales, the Australian Bureau of Statistics reported short term resident returns in April 2024 were 29% higher than April 2023. USa: We achieved a new annual record. The previous highest annual USA sales was AUD $1.0 million in FY19. Sales of Travelan increased 74% to AUD $1.1 million for the full financial year to June 2024 compared to AUD $0.6 million for FY23. Sales of Travelan increased 546% to AUD $0.3 million in the June 2024 Quarter compared to AUD $0.05 million in the June 2023 Quarter. Immuron's experience in the USA follows the International Trade Administration Total U.S. citizen international visitor departures from the United States in April 2024 being 8% higher than in April 2023.
Stock_Titan
Posted - 4 months ago
$IMRN Immuron announces record Travelan® sales globally, Australia and USA
https://www.stocktitan.net/news/IMRN/immuron-announces-record-travelan-r-sales-globally-australia-and-1pvntym9vthz.html